Sutureless aortic valve replacement in pure aortic regurgitation: expanding the indications.
Perceval
Pure aortic regurgitation
SU-AVR
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
22 Aug 2022
22 Aug 2022
Historique:
received:
06
04
2022
accepted:
13
08
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
25
8
2022
Statut:
epublish
Résumé
In the era of transcatheter methods, patients presenting with a pure aortic regurgitation (AR) are not considered eligible for transcatheter treatment and therefore require another less invasive surgical option. We sought to review our experience with sutureless aortic valve replacement (SU-AVR) in patients presenting with symptomatic pure AR, which until now is a contraindication for implementation of sutureless valve prostheses in Europe. Between April 2018 and June 2021, 80 consecutive patients underwent a SU-AVR for various indications at our institution. We analyzed the outcomes and postoperative complications of 12 patients presenting with a pure severe AR undergoing SU-AVR using Perceval (Corcym). The mean age of the patients was 67 ± 9.1 years old. All patients presented with symptomatic pure AR. Patients presented with multiple comorbidities as reflected by the mean EuroSCORE-II of 3.6 ± 2.6%. Six patients (50%) underwent a concomitant CABG procedure. The mean operating- and cross clamp time was 127.25 ± 45.9 and 40.33 ± 17.3 min respectively. All isolated SU-AVR were performed via J-sternotomy or right anterolateral thoracotomy. There were no cases of device dislocation. No patients presented with a paravalvular leakage. We observed excellent mean postoperative pressure gradient at follow-up 5.7 ± 1.5 mmHg. Our experience with SU-AVR shows the feasibility of sutureless technologies in the aortic valve surgery due to pure AR. Besides the great technical success and excellent hemodynamics, SU-AVR in severe AR offers a great opportunity of reducing the invasivity of the surgical procedure and potentially reducing hospital cost without compromising the postoperative outcomes and in-hospital length of stay.
Sections du résumé
BACKGROUND
BACKGROUND
In the era of transcatheter methods, patients presenting with a pure aortic regurgitation (AR) are not considered eligible for transcatheter treatment and therefore require another less invasive surgical option. We sought to review our experience with sutureless aortic valve replacement (SU-AVR) in patients presenting with symptomatic pure AR, which until now is a contraindication for implementation of sutureless valve prostheses in Europe.
METHODS
METHODS
Between April 2018 and June 2021, 80 consecutive patients underwent a SU-AVR for various indications at our institution. We analyzed the outcomes and postoperative complications of 12 patients presenting with a pure severe AR undergoing SU-AVR using Perceval (Corcym).
RESULTS
RESULTS
The mean age of the patients was 67 ± 9.1 years old. All patients presented with symptomatic pure AR. Patients presented with multiple comorbidities as reflected by the mean EuroSCORE-II of 3.6 ± 2.6%. Six patients (50%) underwent a concomitant CABG procedure. The mean operating- and cross clamp time was 127.25 ± 45.9 and 40.33 ± 17.3 min respectively. All isolated SU-AVR were performed via J-sternotomy or right anterolateral thoracotomy. There were no cases of device dislocation. No patients presented with a paravalvular leakage. We observed excellent mean postoperative pressure gradient at follow-up 5.7 ± 1.5 mmHg.
CONCLUSIONS
CONCLUSIONS
Our experience with SU-AVR shows the feasibility of sutureless technologies in the aortic valve surgery due to pure AR. Besides the great technical success and excellent hemodynamics, SU-AVR in severe AR offers a great opportunity of reducing the invasivity of the surgical procedure and potentially reducing hospital cost without compromising the postoperative outcomes and in-hospital length of stay.
Identifiants
pubmed: 35996140
doi: 10.1186/s13019-022-01959-8
pii: 10.1186/s13019-022-01959-8
pmc: PMC9394035
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Informations de copyright
© 2022. The Author(s).
Références
Ann Cardiothorac Surg. 2015 Mar;4(2):100-11
pubmed: 25870805
J Clin Med. 2021 Jul 12;10(14):
pubmed: 34300238
J Thorac Cardiovasc Surg. 1963 Dec;46:726-36
pubmed: 14099081
Ann Thorac Surg. 1996 Aug;62(2):596-7
pubmed: 8694642
Eur J Cardiothorac Surg. 2018 Oct 1;54(4):768-773
pubmed: 29617925
World J Cardiol. 2018 Sep 26;10(9):119-122
pubmed: 30344959
Eur J Cardiothorac Surg. 2021 Oct 22;60(4):727-800
pubmed: 34453161
J Invasive Cardiol. 2020 Aug;32(8):302-309
pubmed: 32737265
J Thorac Cardiovasc Surg. 2000 Oct;120(4):660-7
pubmed: 11003745
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23
pubmed: 23084102
Curr Cardiol Rep. 2020 Jul 28;22(9):98
pubmed: 32725310
Rev Esp Cardiol (Engl Ed). 2018 Feb;71(2):110
pubmed: 29425605
J Thorac Dis. 2021 Jun;13(6):3392-3398
pubmed: 34277035
Can J Cardiol. 2015 Jan;31(1):63-8
pubmed: 25547552
Eur J Cardiothorac Surg. 2008 Apr;33(4):537-41
pubmed: 18255305
Eur J Cardiothorac Surg. 2016 May;49(5):e127-33
pubmed: 26984984
J Am Coll Cardiol. 2018 Apr 3;71(13):1417-1428
pubmed: 29598861
Interact Cardiovasc Thorac Surg. 2009 Dec;9(6):1021-2
pubmed: 19770135
Ann Surg. 1997 Oct;226(4):421-6; discussion 427-8
pubmed: 9351710
Ann Cardiothorac Surg. 2015 Jan;4(1):3-14
pubmed: 25694971
Thorac Cardiovasc Surg. 2020 Oct;68(7):602-607
pubmed: 31003238
Ann Thorac Surg. 2021 Sep 24;:
pubmed: 34563505